Abstract: Radiation therapy is a valuable option for treatment of skin cancer. In order to deliver the radiation dose to the superficial skin tumor, an X-ray source, electron beam radiation therapy or a radioisotope is applied. The effectiveness of these procedures is well established in the literature. Findings of some recent studies have indicated that beta particles can be of particular interest in suppressing skin tumor growth. Betaemitting radioisotopes are favorable because of the short penetration depth of their emitted particles. Beta radiation can induce significant damage in superficial skin tumor, and at the same time, result in enhanced protection of the underlying healthy tissues. In this study, we propose the design of a patch that can be used in beta radiation therapy of skin cancer patients.
Introduction
Skin cancer is one of the most common types of malignancies for which a variety of therapeutic options are available. Though surgery is considered as the gold standard, cryotherapy, photodynamic therapy, chemotherapy, and radiation therapy are also options for treatment [1] .
These non-surgical procedures are particularly preferred by patients for treatment of clearly visible pathologies, e.g. located in the face, as they are associated with more favorable cosmetic results.
Application of ionizing radiation in the management of the skin cancer is interesting not only because of favorable cosmetic outcomes [2] but is also supported by its proven effectiveness in treating several specific types of cancer. Skin tumors are generally superficially-located tumors, for which superficial radiation therapy is commonly used. The superficial dose is usually delivered using a low energy X-ray sources, electron beam radiation therapy or a radioisotope [3] . The potential therapeutic benefits of beta particles have encouraged the use of betaemitting isotopes for radiation therapy of skin tumors as well. Beta radiation, due to its short range, penetrates a few millimeters in the tissue resulting in severe damage to the superficial target structure with minimum side effects to the healthy tissue nearby. Because of the superficiality of the skin tumors, beta radiation would be an interesting option in the management of the skin cancer. For example, 32 P patches have been used, and a study confirmed complete tumor regression in an animal model of skin cancer in a 40 Gy single-dose scheme [4] . In other similar studies, skin patches coated with beta emitter radioisotope 166 Ho were successfully applied to treat Bowen's disease where radioactive patches were put on ______ *Corresponding author: Ali Pashazadeh: Chair for Catheter Technologies,the surface of skin cancer for time periods of 30 to 60 min to deliver a radiation dose of 35 Gy [5] . Similarly, radioactive patches coated with 90 Y have been prepared and tested to control superficial tumors in mice. Radioactive patches of up to 100 MBq radioactivity used in that study showed to be a promissory effective treatment for fibrosarcoma [6] .
Our proposed concept of integrating a beta-emitting radioisotope in a scaffold structure with hydrogel layers could be universally applicable. The current paper describes the design of it, and the procedure that it can be applied to the patient.
Method and material
The scaffold used in this study was fabricated by a custom melt electrospinning writing (MEW) 3D printer from medical grade polycaprolactone. For technical details of the device refer to [7] .
The scaffold was fabricated in the dimension of 20 by 60 mm 2 . Afterwards, the surface was treated with O2 plasma (Plasma Cleaner PDC-32G, Harrick Plasma). Plasma treatment of MEW scaffolds was done for 10 minutes, in two 5-minute sessions for treating both sides of it. Plasma treating is a technique that is usually used for pre-treating of a surface before coating or printing. It results in cleaning of the surface of the scaffold from the foreign contamination, making it ready for the following processing step.
The next step was loading the particles on the plasma treated scaffold. The scaffold was first cut into smaller scaffold pieces and then embedded in the solution containing 90 Sr particles. 90 Sr particles were used as proofof-principle to avoid working in a dedicated nuclear facility but can be replaced with any beta-emitting radioisotope in a real scenario. For 90 Sr coating, the scaffold was immersed in a 500 ml of 1 M solution of 90 Sr salt for 4 hours. Then, the solution was removed, and the scaffold was allowed to dry at room temperature.
Then, to evaluate the load of 90 Sr particles on the scaffold, it was imaged via SEM (TM3000 SEM, Hitachi) (figure 1).
A potential scenario involving beta radiation therapy of skin cancer using the proposed method is illustrated in figure 2 . First, shape and size of the tumor on the skin surface are determined (figure 2.1). Based on the size and shape of the skin tumor, a scaffold is fabricated. It is then treated with plasma and loaded with a desired betaemitting radioisotope to have a tumor-specific radioactive scaffold ( figure 2.2) . In order to provide isolation between the skin and the radioactive scaffold, skin is covered and protected with a very thin hydrogel layer ( figure 2.3) . The scaffold adheres to a thick hydrogel layer ( figure 2.4 ). This layer acts as a shielding to protect environment from radiation. Finally, the radioactive scaffold with its shielding hydrogel layer is placed and adhered on top of the protection layer on the tumor surface to irradiate it (figure 2.5). 
Result and discussion
A MEW fabricated scaffold was produced and loaded with 90 Sr particles. The loaded salt in the texture of the scaffold, as the white particles, are clearly seen in the SEM image. Carboxylation of the scaffold surface via O2 plasma treatment facilitated ionic interactions of the dissociated salt upon the scaffold surface resulting in adsorption and nucleation of the 90 Sr particles. The loading procedure took only 4 hours, which means that even short half-life radioisotopes can be easily used in this patch for radiation therapy. This is of pivotal importance in case of rapidly proliferating malignancies that are best treated with short half-life radioisotopes. The short halflife radioisotopes have high dose rate in comparison to long half-life radioisotopes, resulting in faster dose delivering to the tumor.
As the salt particles are coated in the contexture of the scaffold, the amount of the activity on the scaffold can be controlled by changing the pattern of the contexture of the fabricated scaffold. In order to do this, density or thickness of the scaffold can be adjusted based on the need.
The designed technological concept in this study has been optimized for beta-emitting radioisotopes. The protection layer that is placed directly on top of the tumor surface is thin enough to allow short-range beta particles to easily pass through it and reach the tumor. The thick hydrogel layer on top of the radioactive scaffold ensures that radiation in unwanted direction is absorbed in the hydrogel, protecting surrounding critical or healthy organs.
The main target of this approach is treating skin cancer, but it can also be extended to other applications. One potential application could be irradiation of superficial tumors in interventional procedures. A good example of such scenario is radiation therapy of the tumor bed after lumpectomy. After the primary tumor is surgically removed, there is a chance that the tumor bed still contains residual cancerous cells. These cells may be considered a potential risk for the patient as they can lead to the tumor recurrence. As these cells are located in a thin layer of the tumor bed, radioactive patch with shortrange beta radiation can be used for radiation therapy of these cells. This could also lead to reducing the surgical margins accordingly.
With biocompatible and biodegradable materials selected for the scaffold and hydrogel layers, the patch could be placed directly in the tumor bed, as a form of permanent brachytherapy. In this way, the radioactive patch will be gradually dissolved after completing radiation therapy and having deposited the desired amount of cell-killing radiation dose.
Conclusion
The potential application of the radioactive patch introduced here can be used in skin cancer cases that are not suitable for operation or are cosmetically sensitive like tumors located in the face, as well as for patients that cannot tolerate surgery because of their age or health status. As the scaffold can readily be fabricated in the size and shape of the tumor, it could be a base for tumorspecific and personalized radiation therapy.
However, besides the potential advantages of this concept, it should be noted that many further developments are still needed to make it suitable for a real application.
First, the link of the particles to the scaffold context should be tested and improved to ensure that the radioisotopes coated in the scaffold are not released before the treatment duration is completed. This is of key importance not just to deliver the required dose to the target area, but also it is critical from radiation protection standpoint. Another important issue is the estimation of the radiation dose that is coated in the scaffold. Activity concentration is necessary to estimate exposition time required to deliver the desired physical dose.
In conclusion, the proposed method proposed in this study may make it possible to leverage the effectiveness of several beta emitters in the management of the skin cancers with enhanced output to the patient.
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